Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016
Published Aug 10, 2016
56 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016, provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS)
- The report reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Severe Acute Respiratory Syndrome (SARS) therapeutics and enlists all their major and minor projects
- The report assesses Severe Acute Respiratory Syndrome (SARS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acqu

  
Source:
Document ID
GMDHC8351IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Severe Acute Respiratory Syndrome (SARS) Overview81
Therapeutics Development92
  Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Overview91
  Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Comparative Analysis101
Severe Acute Respiratory Syndrome (SARS) Therapeutics under Development by Companies111
Severe Acute Respiratory Syndrome (SARS) Therapeutics under Investigation by Universities/Institutes121
Severe Acute Respiratory Syndrome (SARS) Pipeline Products Glance132
  Clinical Stage Products131
  Early Stage Products141
Severe Acute Respiratory Syndrome (SARS) Products under Development by Companies151
Severe Acute Respiratory Syndrome (SARS) Products under Investigation by Universities/Institutes161
Severe Acute Respiratory Syndrome (SARS) Companies Involved in Therapeutics Development178
  CEL-SCI Corporation171
  GeneCure LLC181
  Inovio Pharmaceuticals, Inc.191
  Nanotherapeutics, Inc.201
  Novavax, Inc.211
  Phelix Therapeutics, LLC221
  Planet Biotechnology Inc.231
  Protein Sciences Corporation241
Severe Acute Respiratory Syndrome (SARS) Therapeutics Assessment259
  Assessment by Monotherapy Products251
  Assessment by Combination Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration311
  Assessment by Molecule Type322
Drug Profiles3416
  CEL-1000 Drug Profile342
  D-3252 Drug Profile361
  Drugs to Inhibit Cathepsin L for Infectious Diseases Drug Profile371
  FDX-000 Drug Profile381
  Gene Therapy for Severe Acute Respiratory Syndrome Drug Profile391
  INO-4500 Drug Profile402
  Middle East respiratory syndrome coronavirus vaccine Drug Profile421
  Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine Drug Profile431
  ML-188 Drug Profile441
  Monoclonal Antibody for SARS Virus Infections Drug Profile451
  RBD-219N1 Drug Profile461
  SARS (virus like particle) vaccine Drug Profile471
  severe acute respiratory syndrome vaccine Drug Profile481
  SSYA-10001 Drug Profile491
Severe Acute Respiratory Syndrome (SARS) Dormant Projects503
Severe Acute Respiratory Syndrome (SARS) Discontinued Products531
Severe Acute Respiratory Syndrome (SARS) Product Development Milestones541
  Featured News &Press Releases541
    Oct 19, 2015: Inovio and Partner Advance MERS Vaccine541
Appendix552
  Methodology551
  Coverage551
  Secondary Research551
  Primary Research551
  Expert Panel Validation551
  Contact Us551
  Disclaimer561

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Severe-Acute-Respiratory-Syndrome-SARS-Pipeline-Review-H2-2016-2088-16359>
  
APA:
Global Markets Direct - Market Research. (2016). Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Severe-Acute-Respiratory-Syndrome-SARS-Pipeline-Review-H2-2016-2088-16359>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.